Search Results for: M Pharmaceutical Enters Into Exclusive
Articles
M Pharmaceutical Enters Into Exclusive Negotiations to Acquire 40J’s January 6, 2017
M Pharmaceutical Inc. recently announced it has executed on a Letter of Intent to acquire the assets of Cincinnati-based private...LIXTE Biotechnology Enters Exclusive Immune Oncology Patent License Agreement With NINDS & NCI February 26, 2024
LIXTE Biotechnology Holdings, Inc. recently announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders...Henlius & Sermonix Announce Strategic Collaboration & Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene January 11, 2024
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. recently announced a strategic collaboration agreement in which Henlius will receive exclusive...Biodexa Enters Agreements to Acquire Exclusive Worldwide License to a Phase 2 Ready Asset for Type 1 Diabetes November 27, 2023
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
Eisai Enters Joint Development Agreement With Blissbio for Antibody Drug Conjugate With Option Rights for Strategic Collaboration May 8, 2023
Eisai Co., Ltd. recently announced it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a….
Soligenix Enters Exclusive Option Agreement With Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease May 1, 2023
Soligenix, Inc. recently announced it has entered into an exclusive option agreement with Silk Road Therapeutics granting the company the...Avenue Therapeutics Enters Transformational License Agreement With AnnJi Pharmaceutical March 2, 2023
Avenue Therapeutics, Inc. recently announced it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. for AJ201,...RespireRx Enters Collaboration With National Institute for Neurological Disorders & Stroke to Advance its Lead GABAkine Toward Clinical Development December 5, 2022
RespireRx Pharmaceuticals Inc. recently announced it has been accepted into the NIH HEAL Initiative NINDS Preclinical Screening Platform for Pain...Ocuphire Pharma Enters Global License Agreement for Development & Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia & Night Vision Disturbances November 8, 2022
Ocuphire Pharma, Inc. recently announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. for the development...Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc March 28, 2022
Eagle Pharmaceuticals, Inc. recently announced it has reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia Pharma Group plc to Eagle by way of a scheme of arrangement under….
Regio Biosciences Enters License Agreement With AstraZeneca for Phase 2a Asset in Peripheral Artery Disease February 9, 2022
Regio Biosciences recently announced it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol….
Regio Biosciences Enters License Agreement With AstraZeneca for Phase 2a Asset in Peripheral Artery Disease February 3, 2022
Regio Biosciences, a Hibiscus BioVentures company, recently announced it has entered into an exclusive license agreement with AstraZeneca to further...Veru Enters Clinical Trial Collaboration & Supply Agreement With Eli Lilly & Company February 1, 2022
Veru Inc. recently announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of….
Eisai Enters Into Exclusive Licensing Agreement With Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator January 6, 2022
Eisai Co., Ltd. recently announced it has entered into a License Agreement granting the exclusive rights for global research, development,...Santhera Enters Exclusive License Agreement With Sperogenix for Vamorolone in Rare Diseases in the Greater China Region January 4, 2022
Santhera Pharmaceuticals recently announced it has entered into an exclusive license agreement with Sperogenix Therapeutics, a China-based company specializing in orphan diseases. Under this agreement….
BIMI International Medical Inc. Enters Into A MOU to Acquire Chongqing Zhuoda Pharmaceutical August 4, 2021
BIMI International Medical Inc. recently announced the signing of a Memorandum of Understanding (MOU) on July 30, 2021 to acquire...Processa Pharmaceuticals Enters Licensing & Development Agreement With Ocuphire Pharma June 23, 2021
Processa Pharmaceuticals, Inc. recently announced it has entered into a licensing agreement with Ocuphire Pharma, Inc. to license in RX-3117....FSD Pharma Enters License Agreement to Develop FDA-Approved Veterinary Drugs March 17, 2021
FSD Pharma recently announced it has entered into a license agreement with Innovet Italia S.R.L., under which Innovet granted the...X-Chem Enters Multitarget Oncology Discovery Research Collaboration & License Agreement With Genentech February 4, 2021
X-Chem, Inc. recently announced it has entered into a research collaboration and license agreement with Genentech, a member of the...Quantum Genomics Enters Exclusive Licensing & Collaboration Agreement With Qilu Pharmaceutical October 22, 2020
Quantum Genomics recently announced it has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical to develop and commercialize….
